|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.
|
25040077 |
2014 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene.
|
19491257 |
2009 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A panel of wild-type and mutant p53 cancer cell lines of different tissues, including pancreas, breast, skin, and lung were used, as well as chronic lymphocytic leukemia (CLL) patients with different TP53 gene status.
|
30318520 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression.
|
12752098 |
2003 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A statistically significant correlation between p53 deletion and progression of CLL was demonstrated.
|
9283589 |
1997 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Abnormalities in ATM and TP53 genes represent important predictive factors in chronic lymphocytic leukemia (CLL); however, the efficacy of CD20 targeting immunotherapy is only poorly defined in the affected patients.
|
24970561 |
2014 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Abnormalities of the p53 gene are known to confer detrimental effects in chronic lymphocytic leukaemia (CLL) and are associated with short survival.
|
14551737 |
2003 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Accordingly, CLL with the 17p deletion (and likely also with sole TP53 mutation) should be treated with alternative strategies.
|
21239840 |
2010 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group.
|
19025975 |
2009 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
Allogeneic hematopoietic stem cell transplantation (alloHSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (CLL) (i.e., refractory to purine analogs, short response (<24 months) to intensive treatments, and/or presence of 17p/TP53 abnormalities).
|
25651976 |
2015 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Although TP53 mRNA levels did indeed vary among the 104 CLL samples examined, this variability resulted primarily from over-expression of TP53 mRNA in 18 samples, all of which lacked TP53 deletion/mutation.
|
25040181 |
2014 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Although chromosome 17p abnormalities and TP53 mutations have been reported as poor prognostic indicators in chronic lymphocytic leukemia (CLL), the impact of aberrant p53 expression as assessed by immunohistochemistry (p53-IHC) has not been defined in patients with CLL treated with chemoimmunotherapy, particularly in the context of other novel markers such as ZAP-70 expression and IgVH mutation status (IgVH MS).
|
19863337 |
2009 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Although NOTCH1 mutated patients were devoid of TP53 disruption in more than 90% cases in both training and validation series, the OS predicted by NOTCH1 mutations was similar to that of TP53 mutated/deleted CLL.
|
22077063 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
Although the detailed molecular mechanisms are still to be defined, our work shows for the first time that in primary B cells, metabolic stressors enhance BTK signaling and suggest that metabolic rewiring to hyperglycemia affects ibrutinib resistance in TP53 deficient chronic lymphocytic leukemia (CLL) lymphocytes.
|
31363127 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
Among different biomarkers (e.g., CD38, chromosomes abnormalities, ZAP-70, TP53, and microRNA [miRNA]), miRNAs have appeared as new diagnostic and therapeutic biomarkers in patients with the CLL disease.
|
28084621 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Among the 509 CLL cases 349 (68.6%) had FISH (4-probe panel) abnormalities: 160 del 13q [45.8% (122-del 13q, 18-biallelic del 13q, 20-monoallelic/biallelic del 13q)], 71 tri 12 (20.3%), 17 del ATM (5%), 12 del p53 (3.4%) and 89 > or = 2 FISH abnormalities (25.5%).
|
16487171 |
2006 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.
|
28427204 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Analogous to +12 CLL with TP53 disruption or del(11q), NOTCH1 mutations in +12 CLL conferred a significantly worse survival compared to that of +12 CLL with del(13q) or +12 only.
|
22207691 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
Analysis of p53 tumor suppressor pathway genes in chronic lymphocytic leukemia.
|
22047081 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
As such, the tremendous efforts made to better understand the functions of p53 in CLL have contributed substantially to recent advances in treating patients with p53-pathway-deficient CLL.
|
31839919 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Assessment of somatic and germline TP53 alterations has now reached the clinic and is required in several circumstances such as the identification of the most effective cancer therapy for patients with chronic lymphocytic leukemia (CLL).
|
29696732 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Asynchronous replication of p53 and 21q22 loci in chronic lymphocytic leukemia.
|
9402974 |
1997 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
At the clinically relevant concentration of fludarabine, TP53-abnormal samples exhibited markedly higher resistance to fludarabine than the remaining CLL samples (P = 0.012); cohort with ATM deletion was not more resistant than wt cells.
|
19018867 |
2009 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia.
|
21570119 |
2011 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
BCL-1 rearrangements and p53 mutations in atypical chronic lymphocytic leukemia with t(11;14)(q13;q32).
|
10980628 |
2000 |